- Home
- TBRG vs ATYR Comparison
TBRG vs ATYR Comparison
Compare TBRG & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBRG
- ATYR
- Stock Information
- Founded
- TBRG 1979
- ATYR 2005
- Country
- TBRG United States
- ATYR United States
- Employees
- TBRG N/A
- ATYR N/A
- Industry
- TBRG
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TBRG
- ATYR Health Care
- Exchange
- TBRG NYSE
- ATYR Nasdaq
- Market Cap
- TBRG 271.5M
- ATYR 228.1M
- IPO Year
- TBRG N/A
- ATYR 2015
- Fundamental
- Price
- TBRG $23.34
- ATYR $3.63
- Analyst Decision
- TBRG Buy
- ATYR Strong Buy
- Analyst Count
- TBRG 3
- ATYR 5
- Target Price
- TBRG $14.67
- ATYR $19.25
- AVG Volume (30 Days)
- TBRG 90.5K
- ATYR 960.8K
- Earning Date
- TBRG 02-27-2025
- ATYR 03-13-2025
- Dividend Yield
- TBRG N/A
- ATYR N/A
- EPS Growth
- TBRG N/A
- ATYR N/A
- EPS
- TBRG N/A
- ATYR N/A
- Revenue
- TBRG $337,674,000.00
- ATYR $235,000.00
- Revenue This Year
- TBRG $1.02
- ATYR N/A
- Revenue Next Year
- TBRG $6.06
- ATYR $1,080.92
- P/E Ratio
- TBRG N/A
- ATYR N/A
- Revenue Growth
- TBRG 0.26
- ATYR N/A
- 52 Week Low
- TBRG $7.55
- ATYR $1.42
- 52 Week High
- TBRG $23.64
- ATYR $4.23
- Technical
- Relative Strength Index (RSI)
- TBRG 83.06
- ATYR 53.70
- Support Level
- TBRG $20.62
- ATYR $3.17
- Resistance Level
- TBRG $23.32
- ATYR $3.83
- Average True Range (ATR)
- TBRG 0.82
- ATYR 0.25
- MACD
- TBRG 0.19
- ATYR -0.02
- Stochastic Oscillator
- TBRG 93.96
- ATYR 43.60
About TBRG TRUBRIDGE INC
TruBridge Inc is a provider of healthcare solutions and services for community hospitals, clinics, and other healthcare systems. It provides services such as Electronic health records & information systems, revenue cycle management, population health, and data management, etc. The segments of the company are RCM, EHR, and Patient Engagement. The company derives maximum revenue from the RCM segment.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.